MedTrace Logo

Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments

NCT06124677 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2023-12-11

No results posted yet for this study

Summary

The goal of this retrospective single-center chat review is to establish the efficacy and safety of a single dose of intravitreal faricimab (Vabysmo®) injection in patients with neovascular age-related macular degeneration (AMD), who were previously treated with aflibercept (Eylea®) and had persisting intraretinal or subretinal fluid despite frequent treatments.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

Faricimab

The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Miklos Schneider, MD, PhD · Rigshospitalet Glostrup

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2023-11-15
Completion
2023-12-01
FDA Drug
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06124677 on ClinicalTrials.gov